文献速递甲状腺疾病

降钙素原作为甲状腺髓样癌替代肿瘤标志物

Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究通过系统检索截至2021年5月的观察性研究,纳入11项比较降钙素原(ProCT)与降钙素(CT)准确性的研究(n=5817例,其中MTC患者335例),采用层次汇总受试者工作特征和双变量方法进行荟萃分析。结果显示血清ProCT对MTC诊断和监测具有高准确性,合并敏感度0.90(95%CI 0.71-0.97)、特异度1.00(95%CI 0.85-1.00),AUC 0.97(95%CI 0.95-0.98)。结论认为ProCT的高准确性及良好分析特性使其有潜力替代CT成为MTC管理的新标准。

要点

  • 血清ProCT对MTC诊断和监测具有高准确性,合并AUC达0.97。
  • ProCT合并敏感度0.90、特异度1.00,阳性预测值99%,阴性预测值2%。
  • ProCT的高准确性及良好分析特性使其有潜力替代降钙素。

核心结论

  • 血清ProCT对MTC诊断和监测具有高准确性,有潜力替代降钙素成为MTC管理的新标准。

研究设计与样本

  • 系统检索截至2021年5月的观察性研究,纳入11项比较ProCT与降钙素准确性的研究(n=5817例患者,其中MTC患者335例),采用QUADAS-2评估质量,行层次汇总ROC和双变量荟萃分析。

主要发现

  • ProCT合并敏感度为0.90(95%CI 0.71-0.97),特异度为1.00(95%CI 0.85-1.00)。
  • ProCT合并AUC为0.97(95%CI 0.95-0.98),阳性预测值99%,阴性预测值2%。

关键数值与推荐

  • ProCT诊断MTC的合并敏感度0.90(95%CI 0.71-0.97),特异度1.00(95%CI 0.85-1.00)。
  • ProCT合并AUC 0.97(95%CI 0.95-0.98),阳性预测值99%,阴性预测值2%。

临床怎么用

  • 对于MTC的诊断和治疗监测,可考虑检测血清ProCT作为降钙素的替代或补充标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Calcitonin (CT) measurement is pivotal in the management of medullary thyroid carcinoma (MTC), but several pitfalls can affect its reliability. Procalcitonin (ProCT) has been reported as a promising alternative MTC tumor marker. OBJECTIVE: This study aimed to determine the ProCT diagnostic accuracy in prediction and treatment monitoring of MTC. METHODS: Electronic databases were searched for observational studies published until May 2021 without language or time restrictions. Studies comparing ProCT and calcitonin accuracy were included. After removing duplicates and exclusion of not-eligible articles, relevant articles were screened independently by 2 reviewers. Eleven studies (4.5% of the identified studies) met the selection criteria. Two reviewers independently extracted data and assessed data quality and validity through QUADAS-2. RESULTS: A meta-analysis was performed on 11 sufficiently clinically and statistically homogeneous studies (n = 5817 patients, 335 MTC patients). Hierarchical summary receiver operating characteristics and bivariate methods were applied. Serum ProCT was found to be a highly accurate test for MTC diagnosis and monitoring. The pooled sensitivity, specificity, positive and negative likelihood ratios, area under the curve, and positive and negative predictive values for ProCT were 0.90 (95% CI: 0.71-0.97), 1.00 (95% CI: 0.85-1.00), 288 (95% CI: 5.6-14 929.3), 0.10 (95% CI: 0.03-0.33), 0.97 (95% CI: 0.95-0.98), 99%, and 2%, respectively. CONCLUSIONS: The high accuracy, compounded with favorable analytical characteristics, give ProCT great potential to replace calcitonin as a new standard of care in the management of MTC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Giovanella L, Garo ML, Ceriani L, et al. Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2021. PMID: 34382653. doi:10.1210/clinem/dgab564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。